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Background. In resource-limited settings, mothers infected with human immunodeficiency virus type 1
(HIV-1) face a difficult choice: breastfeed their infants but risk transmitting HIV-1 or not breastfeed their infants
and risk the infants dying of other infectious diseases or malnutrition. Recent results from observational studies
and randomized clinical trials indicate daily administration of nevirapine to the infant can prevent breast-milk
HIV-1 transmission.
Methods. Data from 5396 mother-infant pairs who participated in 5 randomized trials where the infant was
HIV-1 negative at birth were pooled to estimate the efficacy of infant nevirapine prophylaxis to prevent breast-
milk HIV-1 transmission. Four daily regimens were compared: nevirapine for 6 weeks, 14 weeks, or 28 weeks, or
nevirapine plus zidovudine for 14 weeks.
Results. The estimated 28-week risk of HIV-1 transmission was 5.8% (95% confidence interval [CI], 4.3%–
7.9%) for the 6-week nevirapine regimen, 3.7% (95% CI, 2.5%–5.4%) for the 14-week nevirapine regimen, 4.8%
(95% CI, 3.5%–6.7%) for the 14-week nevirapine plus zidovudine regimen, and 1.8% (95% CI, 1.0%–3.1%) for the
28-week nevirapine regimen (log-rank test for trend, P < .001). Cox regression models with nevirapine as a time-
varying covariate, stratified by trial site and adjusted for maternal CD4 cell count and infant birth weight, indicat-
ed that nevirapine reduces the rate of HIV-1 infection by 71% (95% CI, 58%–80%; P < .001) and reduces the rate
of HIV infection or death by 58% (95% CI, 45%–69%; P < .001).
Conclusions. Extended prophylaxis with nevirapine or with nevirapine and zidovudine significantly reduces
postnatal HIV-1 infection. Longer duration of prophylaxis results in a greater reduction in the risk of infection.
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UNAIDS estimates that 370 000 children became
newly infected with human immunodeficiency virus
type 1 (HIV-1) during 2009 [1]. How to prevent HIV-
1 transmission associated with breastfeeding remains a
concern in resource-constrained settings where the
prevalence of HIV-1 is high among women of repro-
ductive age, safe replacement feeding options are not
available, and breastfeeding is critical for infant
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survival. In these settings, formula feeding is not affordable
and is associated with increased child morbidity and mortality
from diarrheal disease, pneumonia, and malnutrition, as shown
in several studies from sub-Saharan Africa [2–6]. Thus, the
World Health Organization (WHO) recommends exclusive
breastfeeding during the first 6 months of life and continued
breastfeeding with appropriate complementary food through
at least 12 months for infants born to HIV-1–infected women
in resource-limited settings [7].
Five recent randomized controlled clinical trials found that
infant prophylaxis with daily nevirapine for 6, 14, or 28 weeks
during breastfeeding reduced early postnatal HIV-1 transmis-
sion [8–10]. Herein we describe a pooled analysis of individual
data from >5000 mother-infant pairs that participated in these
5 studies to evaluate the combined efficacy of the infant pro-
phylaxis intervention and the effect of duration of infant
prophylaxis.
Pooled analysis of individual-level data is considered the
gold standard when combining data from multiple studies
[11]. Pooled analysis of individual participant data has many
advantages, both clinically and statistically, over meta-analytic
methods that rely solely on reported aggregate data [12, 13].
For example, in the nevirapine prophylaxis setting it is diffi-
cult to compare the risk of postnatal HIV-1 transmission
between mother-to-child transmission studies using only pub-
lished results because of different study inclusion criteria for
participating in the trials (eg, based on maternal CD4 cell
count or infant birth weight) and different exclusion criteria
for the primary analyses (eg, whether to include infants infect-
ed within the first week after birth). Additionally, certain anal-
yses, such as those described below where the effect of infant
prophylaxis is modeled as a time-varying covariate, are not
possible to conduct without pooling individual-level data.
Therefore, we initiated this pooled analysis of data from the 5
aforementioned trials to assess the efficacy of infant nevirapine
prophylaxis to prevent breast-milk transmission of HIV-1.
These 5 trials were included owing to similarity in study design;
no other trials or studies were considered when this analysis
was initiated. The HIV Prevention Trials Network (HPTN)
study 046 [14] was not included in this analysis, as all infants
in that study received at least 6 weeks of nevirapine; that is, 046
did not have a study arm comparable to the control arms of the
other trials included in the pooled analysis.
METHODS
Pooled Analysis Study Population
The analysis presented in this paper includes data from 5 ran-
domized studies: the Breastfeeding, Antiretrovirals and Nutri-
tion (BAN; ClinicalTrials.gov number NCT00164736) trial in
Lilongwe, Malawi; the Post-Exposure Prophylaxis of the Infant
(PEPI; NCT00115648) trial in Blantyre, Malawi; and the 3
Six-Week Extended Nevirapine (SWEN; NCT00061321) trials
in Ethiopia, India, and Uganda. The details of these studies,
including randomization methods and study procedures, have
been reported individually [8–10]. Because of similarities in
the design and conduct of the trials, data from the SWEN
trials were combined in the primary analysis publication [8];
the same convention is employed in this pooled analysis. All
studies were approved by the appropriate institutional review
boards. A summary of the major study design elements is pro-
vided in Table 1; the BAN trial provided infant prophylaxis
for 28 weeks, PEPI for 14 weeks, and SWEN for 6 weeks. In
these studies, infant HIV-1 infection status was determined by
periodic HIV-1 DNA or RNA polymerase chain reaction
(PCR) testing. All randomized infants were included in this
pooled analysis with the following exceptions: if the infant was
HIV-1 infected at birth (defined as HIV-1 first detected at
birth to age 1 week); had no specimen available for HIV-1
testing at birth; had indeterminate HIV-1 status at birth or age
6 months; or died in the first 7 days after birth. In the case of
multiple births (eg, twins), only firstborns were included. To
ensure comparability between the studies, infants from SWEN
and PEPI were excluded if their mothers had baseline CD4
cell counts <200 cells/µL at baseline (enrollment). The results
presented below differ from the primary analyses of these
trials [8–10] because of these exclusions (as well as minor
updates to the study data sets).
For the BAN trial, 1520 infants were randomized into the
infant nevirapine or control arms (excluding the maternal an-
tiretroviral arm); 72 infants were excluded because they were
HIV-1 infected at birth. Of the remaining 1448 infants, 632
were randomized to receive the control regimen of single-dose
nevirapine and 7 days of zidovudine/lamivudine and 816 were
randomized to receive the control regimen plus 28 weeks of
infant nevirapine.
For the PEPI trial, 3397 infants were randomized; 949 were
excluded because they were HIV-1 infected at birth (n = 232),
infant HIV-1 status at birth was unknown (n = 40), the infant
died in the first week (n = 9), maternal baseline CD4 cell
count was <200 cells/µL (n = 627), or the infant was not first-
born (n = 41). Among the remaining 2448 infants, 792 were
randomized to receive the control regimen of single-dose nevi-
rapine and 7 days of zidovudine, 823 were randomized to
receive the control regimen plus 14 weeks of infant nevirapine,
and 833 were randomized to receive 14 weeks of daily nevira-
pine plus zidovudine.
For the SWEN trials, 2037 infants were randomized in the
combined 3 trials; 13 were excluded because they had no spec-
imens before 6 months, and an additional 143 were excluded
because they were HIV-1-infected at birth (n = 94), there were
no birth specimens (n = 36), HIV-1 infection status was
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indeterminate at birth or 6 months (n = 6), or the infant died
in the first week of life (n = 7). Of the remaining 1881 infants,
361 infants had mothers with baseline CD4 cell counts <200
cells/µL or missing, and an additional 20 infants were not
firstborn. Among the remaining 1500 infants, 769 were ran-
domized to receive the control regimen of single-dose nevira-
pine and 731 were randomized to receive the control regimen
plus 6 weeks of infant nevirapine.
Pooled Analysis Endpoints
The primary study endpoints for the pooled analysis were
infant HIV-1 infection and the composite endpoint infant
HIV-1 infection or death (as in [8–10]).
Statistical Methods
The main focus of this pooled analysis was to assess the effica-
cy of nevirapine in preventing HIV-1 infection or death by
age 28 weeks. In the BAN protocol, which had the longest
infant prophylaxis period of all the studies, the week 28 visit
could occur up to 7 days after the infant was 28 weeks old.
Therefore HIV-1 infection and death up to 203 days after
birth were included in the analysis. Similarly, the primary end-
point for the SWEN trials was HIV-1 infection and death up
to day 202. The primary endpoint of the PEPI trial was HIV-1
infection and death by 9 months of age.
The Kaplan-Meier method was used to estimate the proba-
bility of infant HIV-1 infection or death by 203 days. For the
HIV-1 infection endpoint, time until the first positive HIV-1
test was used in the analysis. Infants who did not reach a
study endpoint by 203 days (HIV-1 infection or death) were
right-censored at the last negative HIV-1 test or at 203 days,
whichever occurred first. Estimates allowing for interval cen-
sored endpoints with intervals formed by the last negative and
first positive HIV-1 tests were similar (results not shown) to
those presented below using the Kaplan-Meier estimator.
HIV-1 infection risk estimates treating HIV-1–free death as a
Table 1. Study Design Characteristics
Characteristic BANa PEPI SWEN
Trial site Malawi (Lilongwe) Malawi (Blantyre) Ethiopia, India, Ugandab
Previous ARV exposure Women with previous ART
exposure excluded




sd NVP (200 mg) + twice-daily
zidovudine (300 mg) and
lamivudine (150 mg) for 1 wk
sd NVP (200 mg) except late
presenters
sd NVP (200 mg) + optional




sd NVP (2 mg/kg) + twice-daily
zidovudine (12 mg) and
lamivudine (6 mg) for 1 wk
sd NVP (2 mg/kg) + twice-daily oral
zidovudine (4 mg/kg) for 1 wk
sd NVP (2 mg/kg)
Postpartum intervention
regimen for infant
Control + daily NVP for 28 wk
(10 mg/d weeks 1–2
increasing to 30 mg/d weeks
19–28)
Control + daily NVP for 14 wk (2
mg/kg/d during wk 2; 4 mg/kg/d
weeks 3–14)
Control + daily NVP as above + oral
zidovudine for 14 wk (4 mg/kg
twice daily for weeks 2–5, 3
times daily for weeks 6–8, and
6 mg/kg weeks 9–14)
Control + daily NVP for 6
wk (5 mg/d)
HIV testing schedule Birth +weeks 1, 2, 4, 6, 8, 12,
18, 21, 24, 28, 32, 36, 42, 48
Birth +weeks 6, 9, 14 +months 6,
12, 18, 24
Birth +weeks 1c, 2, 6, 10c,
14 +month 6
Infants randomized 1520 3397d 2037
Breastfeeding counseling Exclusive BF to 24 wk, then
rapid weaning by 28 wk
Exclusive BF to 6 mo, told to
consider weaning
Encouraged to wean
between 4 and 6 moe




No exclusions No exclusions
Infant birth weight > 2 kg No exclusions No exclusions
Abbreviations: ART, antiretroviral therapy; ARV, antiretroviral; BAN, Breastfeeding, Antiretrovirals and Nutrition study; BF, breastfeeding; HIV, human
immunodeficiency virus; PEPI, Post-Exposure Prophylaxis of the Infant study; sd NVP, single-dose nevirapine; SWEN, Six-Week Extended Nevirapine study.
a Mother antiretroviral arm of BAN excluded.
b Immunoglobulin arm from Uganda site excluded.
c India only.
d Only 3276 randomized in the analysis reported by Kumwenda et al [10]; here n = 3397 since enrollment in PEPI continued beyond the cutoff date (7 August
2007) used in the data analysis by Kumwenda et al.
e Weaning advised at 4 months in India, 6 months or earlier in Uganda, 4–6 months in Ethiopia.
f Exclusion threshold changed from 200 to 250 cells/μL midway through the study (24 July 2006).
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Table 2. Baseline Characteristics and Endpoints (HIV Infections and Deaths) of Infants in Pooled Analysisa
BAN PEPI SWEN
28 wk NVP Control 14 wk NVP 14 wk NVP/AZT Control 6 wk NVP Control
No. of mother-infant pairs 816 632 823 833 792 731 769
Baseline characteristics
Maternal age, yb 25 (22–29) 26 (22–29) 25 (23–29) 25 (23–29) 25 (22–29) 24 (22–27) 24 (21–27)
Maternal CD4 count at
baseline/enrollmentb
440 (330.5–594) 443.5 (335–590) 431 (311–609) 447 (334–610)
442 (330.5–618) 446 (312–601) 434 (317–620)
Mode of delivery (%)
Vaginal 93.7 91.9 96.1 96.5 96.3 83.6 81.8
Cesarean 1.0 1.9 2.2 2.8 2.5 14.4 15.7
Instrumental 5.3 6.2 1.6 0.6 1.0 2.0 2.5
Infant sex (%)
Male 50.0 51.4 49.7 49.9 54.4 48.4 55.0
Female 50.0 48.6 50.3 50.1 45.6 51.6 45.0
Infant birth weight (kg)b 3.0
(2.7–3.3)
3.0 (2.7–3.3) 3.1 (2.8–3.3) 3.0 (2.8–3.3) 3.0 (2.8–3.3) 2.9 (2.6–3.2) 3.0 (2.6–3.2)
Endpoints
HIV-1 infection 13 32 26 34 61 39 54
Death (in children without
confirmed HIV-1
infection)
9 9 16 18 17 6 13
Abbreviations: AZT, zidovudine; BAN, Breastfeeding, Antiretrovirals and Nutrition study; HIV-1, human immunodeficiency virus type 1; NVP, nevirapine; PEPI, Post-Exposure Prophylaxis of the Infant study; SWEN,
Six-Week Extended Nevirapine study.
a Mode of delivery missing for 2 infants in BAN and 3 infants in PEPI; birth weight missing for 2 infants in PEPI and 8 infants in SWEN.















competing risk also yielded similar results (not shown). For
SWEN, similar risk estimates were obtained (not shown) on
the basis of combining country-specific Kaplan-Meier
estimates using inverse variance-weights [8]. Differences
between trial arms were assessed using the log-rank test. Cox
proportional-hazards models, stratified by trial site, were used
Figure 1. Kaplan-Meier estimates of cumulative risk of human immunodeficiency virus type 1 (HIV-1) infection (A and C ) and HIV-1 infection or death
(B and D) among infants HIV-1 uninfected at birth, by study arm. Abbreviations: AZT, zidovudine; BAN, Breastfeeding, Antiretrovirals and Nutrition study;
HIV-1, human immunodeficiency virus type 1; NVP, nevirapine; PEPI, Post-Exposure Prophylaxis of the Infant study; SWEN, Six-Week Extended Nevira-
pine study.
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to estimate hazard ratios (HRs) for the study outcomes com-
paring the different intervention and control groups while ad-
justing for the potentially prognostic baseline factors listed in
Table 2. Stratified Cox regression models were also fit with ne-
virapine as a time-varying covariate equal to 1 for the first 6
weeks for infants in the intervention arm of SWEN, for the
first 14 weeks for infants in the intervention arms of PEPI,
and for the first 28 weeks for infants in the intervention arm
in BAN, and equal to 0 otherwise. Because infants were as-
signed randomly to different durations of prophylaxis, model-
ing nevirapine duration as a time-varying covariate provides a
valid method for assessing the effect of nevirapine; this is in
contrast to observational studies where time-varying con-
founding may be present. Proportional hazard models with
trial site as a fixed effect yielded similar results (not shown).
In the BAN study, the independent data and safety moni-
toring board (DSMB) halted enrollment in the control group
after 668 of the planned 806 mother-infant pairs had been en-
rolled in the control arm [9]. Women in the control arm at
the time of the DSMB recommendation were offered a choice
of remaining on the control arm or switching to either the ma-
ternal or infant antiretroviral interventions [15]. Data regarding
mother-infant pairs who switched to an intervention group
after the DSMB recommendation were censored at that time.
RESULTS
Overall, 5396 mother-infant pairs were included in this pooled
analysis. Table 2 shows baseline characteristics of the study
populations. Maternal age and CD4 cell count at baseline were
similar across all 5 trials. The proportion of infants delivered
vaginally was significantly lower in the SWEN trials (Pearson
χ2 test, P < .0001) as cesarean delivery was more common in
the SWEN than BAN or PEPI studies (15.1% vs 2.1%). Infant
sex and birth weight were similar across trials, with slightly
more males in the PEPI and SWEN control arms (P = .07).
The numbers of infants with HIV-1 infection or death by
age 28 weeks are shown in Table 2. Kaplan-Meier estimates of
the cumulative risk of HIV-1 infection are shown in Figure 1A
and 1C and Figure 2A. The estimated risk of HIV-1 infection
by 28 weeks in the control arms of the trials was 9.1% (95%
CI, 7.1%–11.5%) in PEPI, 7.4% (95% CI, 5.7%–9.6%) in
SWEN, and 5.7% (95% CI, 4.1%–8.0%) in BAN (log-rank test
P = .08). Risk of HIV-1 infection by 28 weeks in the SWEN
nevirapine arms was 5.8% (95% CI, 4.3%–7.9%), in the PEPI
nevirapine arm was 3.7% (95% CI, 2.5%–5.4%), in the PEPI
nevirapine plus zidovudine arm was 4.8% (95% CI, 3.5%–
6.7%), and in the BAN nevirapine arm was 1.8% (95% CI,
1.0%–3.1%) (log-rank test for trend, P < .001). Similar results
were obtained for the risk of HIV-1 infection or death
(Figure 1B and 1D and Figure 2B). Risk of HIV-1 infection or
death by 28 weeks in the SWEN nevirapine arms was 6.7%
(95% CI, 5.0%–8.8%), in the PEPI nevirapine arm was 5.8%
(95% CI, 4.3%–7.8%), in the PEPI nevirapine plus zidovudine
arm was 7.2% (95% CI, 5.5%–9.3%), and in the BAN nevira-
pine arm was 3.0% (95% CI, 2.0%–4.5%).
Results of the Cox proportional-hazards analyses of risk
factors for postnatal HIV-1 infection are shown in Table 3. In
both unadjusted and adjusted analyses, daily nevirapine for 14
weeks (with or without zidovudine) or 28 weeks was signifi-
cantly associated with a lower rate of HIV-1 infection. Mater-
nal age, mode of delivery, and infant sex were not significant
risk factors for HIV-1 infection (P > .2 for each covariate). For
the stratified proportional hazards model, the adjusted HR es-
timate for 28 weeks of daily nevirapine vs control was 0.28
(95% CI, .15–.54). Similarly, for a stratified Cox regression
model with nevirapine as a time-varying covariate, the corre-
sponding adjusted HR estimate was 0.29 (95% CI, .20–.42;
P < .001), indicating that extended infant nevirapine prophy-
laxis results in a 71% decrease in the rate of HIV-1 infection
during the period it is being given. There was no evidence that
this decrease in infection rate was modified by maternal CD4
cell count (P = .42). For the model in Table 3, after adjusting
Figure 2. Estimated cumulative risk (with 95% confidence intervals) of
(A) human immunodeficiency virus type 1 (HIV-1) infection or (B) HIV-1
infection or death by 28 weeks among infants HIV-1 uninfected at birth
by study arm. Abbreviations: AZT, zidovudine; BAN, Breastfeeding, Anti-
retrovirals and Nutrition study; HIV-1, human immunodeficiency virus
type 1; NVP, nevirapine; PEPI, Post-Exposure Prophylaxis of the Infant
study; SWEN, Six-Week Extended Nevirapine study.
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for infant prophylaxis, maternal CD4 cell count < 350 cells/µL
was associated with an increased rate of transmission (adjusted
HR estimate, 2.19 [95% CI, 1.71–2.80]; P < .001), and higher
birth weight was associated with a lower rate of transmission
(adjusted HR estimate, 0.64 [95% CI, .48–.85] per 1-kg in-
crease in birth weight; P = .002).
Table 3 also shows the results of the Cox proportional
hazards analyses of risk factors for the composite endpoint
HIV-1 infection or death. Hazard ratio estimates are similar to
those for the HIV-1 infection endpoint. Maternal age, mode
of delivery, and infant sex were not significant risk factors for
HIV-1 infection or death. The estimated HR for 28 weeks of
daily nevirapine vs control was 0.38 (95% CI, .23–.64). Simi-
larly, for a Cox regression model with nevirapine as a time-
varying covariate, the adjusted HR estimate for nevirapine was
0.42 (95% CI, .31–.55; P < .001), indicating that extended
infant nevirapine prophylaxis results in a 58% decrease in the
rate of HIV-1 infection or death.
DISCUSSION
This analysis indicates extended infant prophylaxis with nevi-
rapine or with nevirapine and zidovudine significantly reduces
postnatal HIV-1 infection by 28 weeks. Compared with the
control arms of BAN, SWEN, and PEPI trials, daily nevirapine
for 28 weeks reduces the rate of HIV infection by 71% (95%
CI, 58%–80%; P < .001) and reduces the rate of HIV infection
or death by 58% (95% CI, 45%–69%; P < .001). This pooled
analysis indicates that longer duration of prophylaxis results in
a greater reduction in infection risk in the first 28 weeks of an
infant’s life, in agreement with the HPTN 046 trial [14],
which found that extending infant nevirapine from 6 weeks to
6 months significantly decreased postnatal HIV-1 infection by
54%.
Although this pooled analysis does not include a formal
comparison of safety data from the SWEN, PEPI, and BAN
trials, the individual primary analyses for each of the trials all
led to the conclusion that extended infant daily antiretroviral
prophylaxis is safe. Although data on maternal viral load were
not available for this analysis, confounding of the effect of ne-
virapine by maternal viral load seems unlikely given that
mother-infant pairs were randomized to nevirapine or control
at each trial site and our adjusted pooled analysis included
data on maternal CD4 cell counts at baseline. Another poten-
tial limitation of this analysis is that no formal adjustment is
made for reported breastfeeding. No significant differences in
breastfeeding rates through 28 weeks between trial arms were
reported in any of the studies. In BAN, mothers were
Table 3. Risk Factors of Infant HIV-1 Infection and a Composite Outcome of HIV-1 Infection or Death by 28 Weeks Among Infants Who
Were HIV-1 Uninfected at Birth
Risk Factor
Unadjusteda Adjustedb
Hazard Ratio (95% CI) P Value Hazard Ratio (95% CI) P Value
For HIV-1 infection by 28 wk
Infant NVP 6 wk vs control .80 (.53–1.20) .27 .80 (.53–1.21) .29
Infant NVP 14 wk vs control .39 (.24–.61) <.001 .36 (.23–.57) <.001
Infant NVP + AZT 14 wk vs control .50 (.33–.77) .001c .49 (.32–.75) .001c
Infant NVP 28 wk vs control .29 (.15–.56) <.001 .28 (.15–.54) <.001
Maternal baseline CD4 count (<350 vs ≥350 cells/μL) 2.14 (1.68–2.74) <.001 2.19 (1.71–2.80) <.001
Infant birth weight (per increase of 1 kg) .65 (.49–.86) .002 .64 (.48–.85) .002
For HIV-1 infection or death by 28 wk
Infant NVP 6 wk vs control .73 (.50–1.06) .10 .73 (.50–1.07) .10
Infant NVP 14 wk vs control .49 (.34–.71) <.001 .46 (.32–.67) <.001
Infant NVP + AZT 14 wk vs control .61 (.43–.86) .005c .59 (.42–.84) .003c
Infant NVP 28 wk vs control .39 (.23–.65) <.001 .38 (.23–.64) <.001
Maternal baseline CD4 count (<350 vs ≥350 cells/μL) 1.83 (1.48–2.27) <.001 1.83 (1.50–2.30) <.001
Infant birth weight (per increase of 1 kg) .61 (.49–.78) <.001 .60 (.47–.77) <.001
Abbreviations: AZT, zidovudine; BAN, Breastfeeding, Antiretrovirals and Nutrition study; CI, confidence interval; HIV-1, human immunodeficiency virus type 1;
NVP, nevirapine; PEPI, Post-Exposure Prophylaxis of the Infant study; SWEN, Six-Week Extended Nevirapine study.
a Proportional hazards models with each risk factor as the sole covariate, stratified by trial site. Infant NVP 6 weeks vs control using SWEN data only, stratified by
trial site; infant NVP 14 weeks vs control and infant NPV + AZT 14 weeks vs control using PEPI data only; infant NVP 28 weeks vs control using BAN data only.
b Proportional hazards models adjusted for all variables listed, stratified by trial site.
c Test for proportional hazards assumption 0.025 <P < .05 for all models with infant NPV + AZT; for all other covariates and models P > .05.
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specifically counseled to wean their babies from 24 to 28
weeks with approximately only 33% still breastfeeding at 28
weeks. In SWEN, mothers were encouraged to wean between
4 and 6 months, with only 31% reporting breastfeeding by 6
months. In PEPI, women were told to exclusively breastfeed
for 6 months and consider weaning thereafter; at 6 months
approximately 90% of infants were breastfeeding, with most
women weaning their infants between ages 6 and 9 months.
CONCLUSIONS
This pooled analysis of 5 randomized clinical trials that used
daily infant nevirapine prophylaxis during breastfeeding in re-
source-limited settings confirms the significant efficacy of this
mode of prophylaxis in preventing infant HIV-1 infection and
HIV-1 infection or death by 28 weeks. However, after prophy-
laxis was discontinued, the HIV-1 transmission risk returns if
breastfeeding is continued. Longer duration of prophylaxis was
associated with greater protection. Following the results of the
trials included in this analysis, WHO changed its guidelines to
recommend daily infant nevirapine prophylaxis during breast-
feeding through age 12 months as one of the options for pre-
vention of transmission in breastfeeding infants of HIV-1–
infected women who do not require treatment for their own
health [16]. This analysis supports the recommendation that if
breastfeeding continues through age 12 months, prophylaxis
should also continue, although data on the safety of extending
prophylaxis for longer than 6 months are needed.
Many countries are moving quickly to implement highly
active antiretroviral therapy (HAART) for all HIV-positive
pregnant women prepartum, regardless of CD4 cell count,
and continuing for the duration of breastfeeding [17–19]. This
early treatment strategy also decreases tuberculosis incidence
and transmission of HIV to uninfected sexual partners [20].
However, a large percentage of HIV-positive pregnant women
in developing countries do not access voluntary counseling
and testing until late in pregnancy, thus lessening the impact
of HAART [9, 21]. Furthermore, many countries are reaching
<50% of those patients who need HAART for their own
health [22].
Although maternal treatment is being rapidly adopted, in
settings where maternal treatment is not affordable, available,
or acceptable, infant nevirapine prophylaxis may be a feasible
alternative. Infant nevirapine prophylaxis is an inexpensive,
safe, and effective intervention that allows HIV-1–infected
mothers who do not require treatment for their own health to
breastfeed their infants with reduced risk of HIV transmission.
Infant nevirapine does not require any lab monitoring and
allows overburdened and under-resourced treatment programs
to focus on those women who need treatment for their own
health. While nevirapine is known to select for resistant virus
in infants who become infected despite prophylaxis (resulting
in limited treatment options, especially in resource-limited set-
tings), resistance may also occur in infants who become infect-
ed while their mothers are receiving HAART. Therefore,
alternative prevention strategies should be pursued. Until such
effective alternatives are available, infant nevirapine prophy-
laxis offers a simple intervention that will contribute to
meeting the goal of eliminating mother-to-child HIV-1 trans-
mission worldwide.
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